Sipuleucel-T
Highest phase reached
Approved
Drug type
Cell
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Cell
- Drug name
- Sipuleucel-T
- apc 8015
- APC-8015
- apc8015
- APC8015
- provenge
- PROVENGE
- sipuleucel t
- sipuleucel t mart
- sipuleucel t mi
- sipuleucel t usan
- sipuleucel t usp monograph
- sipuleucel t vandf
- sipuleucel t who dd
- sipuleucel-T
- Sipuleucel-t
- Sipuleucel-T
- SIPULEUCEL-T [MART.]
- SIPULEUCEL-T [MI]
- SIPULEUCEL-T [USAN]
- SIPULEUCEL-T [USP MONOGRAPH]
- SIPULEUCEL-T [VANDF]
- Sipuleucel-t [WHO-DD]
- Sipuleucel-T Injection
- ATC classification codes
- L03AX17
Sources for recorded values
- CAS registry numbers
- 917381-47-6
- ChEMBL ID
- CHEMBL1237024
- RxNorm IDs (RxCUI)
- 997261
- FDA ingredient codes (UNII)
- 8Q622VDR18
- First in class
- Yes
- Orphan designation
- No
Mechanisms of action
- Mechanism
- Prostatic acid phosphatase binding agent
- Action type
- BINDING_AGENT
- Target
- Prostatic acid phosphatase
- Protein identifier
- P15309
Open Targets mechanisms
- Mechanism
- Prostatic acid phosphatase binding agent
- Action type
- BINDING AGENT
- Target
- Prostatic acid phosphatase
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000196
- Subject identifier
- D011471
- Condition
- Neoplasms
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000673
- Subject identifier
- D011471
- Condition
- Prostatic Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0001663
- Subject identifier
- D011471
- Condition
- Prostatic Neoplasms, Castration-Resistant
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0008315
- Subject identifier
- D064129
- Condition identifier
- EFO_0000196
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000616
- Condition identifier
- EFO_0000673
- Highest recorded phase
- 3
- Condition identifier
- EFO_0001663
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005070
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005082
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0005105
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0008315
- Condition identifier
- MONDO_0008315
- Highest recorded phase
- 4
- Event
- back pain
- Reports
- 88
- Reporting signal score
- 34.9214
- Event
- blood pressure decreased
- Reports
- 50
- Reporting signal score
- 39.6358
- Event
- body temperature increased
- Reports
- 28
- Reporting signal score
- 31.9122
- Event
- chills
- Reports
- 300
- Reporting signal score
- 561.459
- Event
- citrate toxicity
- Reports
- 21
- Reporting signal score
- 131.746
- Event
- culture positive
- Reports
- 137
- Reporting signal score
- 736.293
- Event
- dehydration
- Reports
- 80
- Reporting signal score
- 40.7814
- Event
- disease progression
- Reports
- 95
- Reporting signal score
- 80.3313
- Event
- drug hypersensitivity
- Reports
- 3
- Reporting signal score
- 36.7129
- Event
- gram stain positive
- Reports
- 14
- Reporting signal score
- 67.3374
- Event
- haematocrit decreased
- Reports
- 34
- Reporting signal score
- 38.2777
- Event
- haemoglobin decreased
- Reports
- 94
- Reporting signal score
- 62.9212
- Event
- hospitalisation
- Reports
- 75
- Reporting signal score
- 39.0078
- Event
- hydronephrosis
- Reports
- 22
- Reporting signal score
- 36.2719
- Event
- ill-defined disorder
- Reports
- 162
- Reporting signal score
- 431.066
- Event
- infusion related reaction
- Reports
- 104
- Reporting signal score
- 127.545
- Event
- infusion site extravasation
- Reports
- 19
- Reporting signal score
- 31.7883
- Event
- injection site pain
- Reports
- 2
- Reporting signal score
- 29.92
- Event
- malaise
- Reports
- 182
- Reporting signal score
- 82.48
- Event
- metastases to bone
- Reports
- 35
- Reporting signal score
- 58.5742
- Event
- microbiology test abnormal
- Reports
- 20
- Reporting signal score
- 120.978
- Event
- mononuclear cell count abnormal
- Reports
- 54
- Reporting signal score
- 346.758
- Event
- prostate cancer metastatic
- Reports
- 16
- Reporting signal score
- 44.4362
- Event
- prostatic specific antigen increased
- Reports
- 45
- Reporting signal score
- 104.441
- Event
- pyrexia
- Reports
- 178
- Reporting signal score
- 70.2852
And 5 more, listed on the interactive page.
- NCT00005947
- NCT00027599
- NCT00065442
- NCT00715078
- NCT00715104
- NCT00779402
- NCT00901342
- NCT01133704
- NCT01338012
- NCT01487863
- NCT01706458
- NCT01818986
- NCT01832870
- NCT02036918
- NCT02159950
- NCT02463799
- NCT02793219
- NCT02793765
- NCT03024216
- NCT05806814
- NCT06100705
- NCT01431391
- NCT01477749
- NCT03686683
- NCT01560923
And 2 more, listed on the interactive page.
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Natural product
- No
Related records
Trials (35)
- 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T
- A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer
- A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
- APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
- Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
- Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
- Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
- Docetaxel Followed by Provenge in Metastatic Prostate Cancer
- Immune Monitoring Protocol in Men With Prostate Cancer Enrolled in a Clinical Trial of Sipuleucel-T
- Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
- Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing
- Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
- Open Label Study of Sipuleucel-T in Metastatic Prostate Cancer
- Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
- Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
- Provenge Followed by Docetaxel in Castration-Resistant Prostate Cancer
- PROvenge Treatment and Early Cancer Treatment
- Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
- Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Approved for (2)
- Neoplasm
- Prostate cancer
In development for (3)
- Metastatic prostate carcinoma Phase 3
- Prostate adenocarcinoma Phase 3
- Prostate carcinoma Phase 3
Targets (1)
- ACP3 Prostatic acid phosphatase binding agent